CS
STRO icon

Credit Suisse’s Sutro Biopharma STRO Stock Holding History

Credit Suisse’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Hold
0
– -$16 – 3677
2022
Q4 		– Sell
-28
Closed -$1.95K – 3681
2022
Q3 		$2K Buy
28
+23
+460% +$1.36K ﹤0.01% 3762
2022
Q2 		$0 Sell
5
-2,712
-100% -$151K ﹤0.01% 4294
2022
Q1 		$223K Sell
2,717
-114
-4% -$10.8K ﹤0.01% 3348
2021
Q4 		$421K Buy
2,831
+737
+35% +$132K ﹤0.01% 3940
2021
Q3 		$396K Buy
2,094
+165
+9% +$31.4K ﹤0.01% 3958
2021
Q2 		$358K Buy
+1,929
New +$378K ﹤0.01% 4024
2021
Q1 		– Sell
-2,879
Closed -$625K – 4545
2020
Q4 		$625K Buy
+2,879
New +$477K ﹤0.01% 3675

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Credit Suisse's STRO Position: Q1 2023 in Review

Credit Suisse held its Sutro Biopharma (STRO) position steady in Q1 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3677.

Credit Suisse first reported a position in STRO in Q4 2020 and has held it in 7 quarters since. The position peaked at $625K in Q4 2020. 115 funds tracked by Wall St. Rank hold STRO as of Q1 2023.

  • Credit Suisse held 0 shares of Sutro Biopharma worth $0 as of Q1 2023.
  • Credit Suisse left its Sutro Biopharma share count unchanged in Q1 2023.
  • Sutro Biopharma made up ﹤0.01% of Credit Suisse's portfolio in Q1 2023, its #3677 holding.
  • Credit Suisse first reported a position in Sutro Biopharma in Q4 2020 and has held it in 7 quarters since.
  • Credit Suisse's Sutro Biopharma position peaked at $625K in Q4 2020.
  • 115 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.